|Prof. Ugur Sahin M.D.||Co-Founder, CEO & Member of Management Board||716.89k||N/A||1966|
|Prof. Christoph Hubert Huber||Co-Founder & Member of Supervisory Board||N/A||N/A||1945|
|Dr. Sierk Poetting Ph.D.||MD, COO & Member of Management Board||722.82k||N/A||1974|
|Mr. Ryan Richardson||Chief Strategy Officer, MD & Member of Management Board||637.37k||N/A||1980|
|Mr. Sean Marett||Chief Bus. Officer, Chief Commercial Officer & Member of Management Board||799.97k||N/A||1966|
|Dr. Ozlem Tureci||Chief Medical Officer & Member of Management Board||709.77k||N/A||1968|
|Mr. Jens H. Holstein||CFO & Member of Management Board||N/A||N/A||1963|
|Sylke Maas Ph.D.||VP of Investor Relations and Bus. Strategy||N/A||N/A||N/A|
|Dr. James Timothy Patrick Ryan Ph.D.||VP of Legal & Intellectual Property||N/A||N/A||N/A|
|Michael Boehler||MD & Head of Global External Communications||N/A||N/A||N/A|
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.